CHENG-MAW HOREY-HENG HUYAO-MING WUMING-CHIH HOPO-HUANG LEE2021-11-252021-11-252021-06-0125085778https://scholars.lib.ntu.edu.tw/handle/123456789/587743Introduction: The success of immunotherapy for patients with hepatocellular carcinoma (HCC) suggest that immune dysregulation occurs in HCC patients. This warrants an immuno-oncological risk assessment in the platform of liver transplantation. Methods: This retrospective single-center study analyzed risk factors for—particularly cross-matching performed through conven­tional complement-dependent cytotoxicity cross-match tests—and the outcomes of HCC recurrence following living donor liver trans­plant. Results: A total of 71 patients were included. The median follow-up period was 29.1 months. Seventeen (23.9%) patients had post­transplant HCC recurrence, and their 1-, 3-, and 5-year survival rates were 70.6%, 25.7%, and 17.1%, respectively, which were inferior to those of patients without HCC recurrence (87.0%, 80.7%, and 77.2%, respectively [p < 0.001]). In addition to microvascular invasion, positive cross-match results for B cells at 37°C (B- 37ºC) or T cells at 4°C (T- 4ºC) was associated with inferior overall survival in mul­tivariable analysis after adjustment for tumor status beyond Milan criteria and elevated alpha-fetoprotein levels. Rejection alone can­not be the mechanism underlying the effects of positive cross-match results on patient outcomes. Adjusted survival curves suggested that positive cross-match B- 37ºC or T- 4ºC was associated with inferior recurrence-free and patient survival, but the robustness of the finding was limited by insufficient power. Conclusions: Additional large-scale studies are required to validate positive cross-match as an immuno-oncological factor associated with HCC recurrence and inferior patient survival.enjournal article10.14701/ahbps.LV-OP-1-62-s2.0-85116258440https://api.elsevier.com/content/abstract/scopus_id/85116258440